| Autor: |
Bailey M; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Morand S; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Royfman R; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Lin L; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Singh A; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Stanbery L; Gradalis, Inc., Dallas, TX 75006, USA., Walter A; Gradalis, Inc., Dallas, TX 75006, USA.; Department of Gynecologic Oncology, Promedica, Toledo, OH 43614, USA., Hamouda D; Department of Medicine, University of Toledo, Toledo, OH 43614, USA., Nemunaitis J; Gradalis, Inc., Dallas, TX 75006, USA. |
| Abstrakt: |
The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi's), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi's have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in BRCA wild-type, homologous recombination proficient (HRP) cancers. Therefore, attempts have been made at combination therapy involving PARPi to improve patient outcomes. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated underwhelming results involving ovarian cancer. Many are searching for reliable biomarkers of immune response to increase efficacy of ICI therapy involving ovarian cancer. In this review, we examine the evidence supporting the combination of PARPi and ICIs in ovarian cancer, which is still lacking. |
